D
ESPITE THE WELL-DOCUmented effects of hormone replacement therapy (HRT) on reducing menopausal symptoms, 1 and risk of osteoporosis, 2 and a potentially beneficial effect on the primary prevention of coronary heart disease, 3, 4 concerns about breast cancer cause many women to avoid taking estrogens. Recent studies demonstrating that the selective estrogen receptor modulators tamoxifen 5 and raloxifene 6 reduce the incidence of hormone receptor-positive breast cancer have focused new attention on associations between hormones and breast cancer risk. Whether HRT use increases risk of breast cancer is controversial. A considerable amount of epidemiological data supportsamodestincreaseinriskofbreast cancer with long-term hormone use. For example, in a combined analysis of 51 studies,therelativerisk(RR)ofbreastcancer was 1.35 (95% confidence interval [CI], 1.21-1.49) for women who used HRT for 5 years or more compared with never-users. 7 However, Shairer et al 8 proposed that postmenopausal hormone exposure specifically promotes the growth of less aggressive, slow-growing tumors. Althoughtwo 8, 9 ofthree 10 studiesreported differencesintheassociationbetweenHRT use and risk of invasive vs in situ breast cancer, it has not been determined whether the effect of HRT use on breast cancer incidence varies among histologicaltypesofinvasivecarcinomas.Clinically, significant differences in prognosis exist betweeninfiltratingductalandlobularcarcinomas, which account for 85% to 90% of invasive tumors, 11, 12 and the less common medullary, papillary, tubular, and mucinous tumors that have a lower risk of axillary node metastases and a more favorable prognosis. 12, 13 Information regardingdifferencesinHRT-associatedrisk across histological types of breast cancer could have implications for determining the risks and benefits of hormonally related disease prevention strategies.
Using data from a large cohort of postmenopausal women, we examined whether the association between HRT use and breast cancer incidence differs among 3 histologically defined groups of breast tumors: ductal carcinoma in situ (DCIS), invasive carcinomas with favorable histologies, and invasive ductal and/or lobular carcinoma.
METHODS
The Iowa Women's Health Study is a prospective cohort study designed to examine the effect of several risk factors on the incidence of cancer in postmenopausal women aged 55 to 69 years at baseline. Detailed methods for recruitment and data collection were published previously. 14, 15 Briefly, potential participants were selected randomly from the 1985 Iowa Department of Transportation driver's license list. The list contained approximately 94% of all Iowa women in the target age range. In January 1986, 98 029 eligible women were mailed a 16-page, self-administered questionnaire, and 41 837 eligible women completed and returned the questionnaire, yielding a response rate of 42.7%. From the information available on the driver's license list and the 1980 US Census for Iowa, it was determined that responders were approximately 3 months older, were 0.4 kg/m 2 lower in body mass index (BMI), and slightly more likely to live in rural counties. However, we have shown that the incidence of breast cancer is similar among respondents and nonrespondents (RR, 1.01; 95% CI, 0.9-1.1). 15 The population at risk for developing breast cancer excluded women who at baseline (1) were premenopausal (n = 569), (2) reported a previous total or partial mastectomy (n = 1870), or (3) reported a personal history of nonskin cancer (n = 2293). The at-risk cohort included 37 105 women.
Risk Factor Assessment
Self-reported information ascertained from the baseline mailed questionnaire included birth date, education, cigarette smoking history, personal history of cancer, and history of cancer in female relatives (no information on the number of relatives affected or the relative's age at diagnosis was collected). Reproductive history included information on outcome of each pregnancy, length of each pregnancy, and age at beginning of each pregnancy. Women were asked whether they had ever used pills, other than birth control pills, that contain estrogen or other female hormones and how long they had used them. Participants also were asked to record their height, current weight, and weight at age 18 years; from this information, current BMI (calculated as weight in kilograms divided by the square of height in meters) and BMI at age 18 years were computed. To determine waist-to-hip ratio, a paper tape and detailed instructions for circumference measurements of the waist and hips were enclosed with the questionnaire. Kushi et al 16 verified the high validity and reliability of this approach to obtaining anthropometric data in this population. Information on menstrual history included age at menarche and age at menopause; menstruation in the last year; and the type of menopause (ie, natural, surgical, medical, or other). Usual alcohol consumption was assessed using the Harvard semiquantitative food frequency questionnaire developed by Willett et al, 17 and has been described in detail elsewhere. 18, 19 Four follow-up questionnaires were mailed in 1987, 1989, 1992 , and 1997 to collect information on incident selfreported disease, vital status, and current residence. On the second follow-up survey, participants were asked whether they had ever undergone mammography and the length of time since last mammography.
Identification of Cases
The cohort has been followed up continuously for 11 years (January 1986-December 1996 The first 4 digits of this code describe tumor histology, the fifth digit describes behavior (eg, 2 = carcinoma in situ, 3 = malignant, primary site), and the sixth digit describes histological grade. For these analyses, the first 5 digits were used to classify breast cancer cases into 4 groups: (1) DCIS, (2) invasive carcinoma with a favorable prognostic histology (ie, mucinous, medullary, tubular, papillary), (3) invasive ductal and/or lobular carcinoma, and (4) other (excluded from analysis).
Statistical Analysis
The type of HRT use was categorized as never use, 5 years or fewer or more than 5 years for ever-users, current users, and past users. Anthropometric risk factors were stratified into tertiles. Women who reported a mother, sister, or daughter with breast cancer were considered to have a positive family history of breast cancer. Alcohol abstainers were women whose reported alcohol intake was 0 g/d, and alcohol consumers were classified into 2 groups based on a median split of daily alcohol intake (Ͻ4.0 or Ն4.0 g/d). Other characteristics such as age at menarche, menopause, first live birth, parity, and type of menopause were classified into logical categories.
Person-years of follow-up were computed for each woman as the amount of time since completion of the baseline questionnaire to 1 of the following events: (1) breast cancer diagnosis, (2) death (if in Iowa), (3) a move out of Iowa (if date known), (4) midpoint of interval between last contact date and either date of next follow-up or December 31, 1996 (if date of move was unknown), and (5) midpoint of interval between date of last contact and date of death (for non-Iowa deaths). For women without 1 of these events, follow-up was to December 31, 1996 .
Cox proportional hazards regression was used to determine age-adjusted and multivariate-adjusted associations between HRT use and breast cancer incidence. The RRs and 95% CIs were computed within categories of risk factors for each histological type of breast cancer. To compare respective regression coefficients across tumor types, multivariate polychotomous logistic regression was used to account simultaneously for the 4 possible outcomes (ie, noncase, DCIS, invasive carcinoma with a favorable histology, invasive ductal or lobular carcinoma). The dependent variable was treated as a polychotomous nominal variable, and the logit estimator always compared histologically defined cases (eg, DCIS) with noncases. 20 These regression coefficients agreed closely with those computed from the multivariate Cox proportional hazards analysis. Analyses were performed using PROC PHREG and PROC CATMOD of the SAS statistical software package (SAS Institute Inc, Cary, NC).
RESULTS
After 371 477 person-years of followup, 1520 incident breast cancer cases occurred in the at-risk cohort. The distribution of breast cancer cases by histology is shown in TABLE 1; 11.5% were DCIS, 5.4% were invasive breast cancer with a favorable histology, and 76.6% were infiltrating ductal or lobular carcinoma. Fifteen women diagnosed as having lobular carcinoma in situ (LCIS), and 84 women with nonepithelial tumors and rare or poorly defined tumors were excluded from analysis.
Age-adjusted RRs for HRT use and other breast cancer risk factors were computed for each tumor type (TABLE 2). Risk of invasive carcinoma with a favorable histology was positively associated with duration of ever use of HRT (P for trend = .009). There were no relationships with duration of ever use for DCIS or for invasive ductal or lobular carcinoma. Invasive carcinoma with a favorable histology and invasive ductal or lobular carcinoma were significantly and positively associated with increasing BMI (P for trend = .03 and Ͻ.001, respectively). Conversely, there were inverse dose-response relationships between each of the invasive tumor types and BMI at age 18 years. Increasing waist-to-hip ratio was associated with increased risks of the favorable histological tumors (P for trend = .02), and invasive ductal or lobular carcinoma (P for trend Յ.001). The incidence of DCIS was not related to BMI, BMI at age 18 years, or waist-tohip ratio. Age at menarche, age at menopause, and type of menopause were not related to the age-adjusted incidence of any tumor type. For invasive carcinoma with a favorable histology, there was a nonsignificant inverse association with parity. A positive association between age at first birth and breast cancer risk was observed for all histological tumor types. For women with a family history of breast 
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use (Ͼ5 years) of HRT had a lower current BMI, BMI at age 18 years, and waistto-hip ratio. Never-users reported a younger age at menopause and at first live birth. A higher proportion of neverusers reported a natural menopause. Independent effects of HRT use for all types of breast cancer combined and for each tumor type were assessed in multivariate Cox proportional hazards regression after adjusting for age, BMI, BMI at age 18 years, waist-to-hip ratio, age at menarche, age at menopause, type of menopause, parity, age at first birth, family history of breast cancer, and alcohol intake. The multivariate-adjusted RRs of all breast cancer combined among women who ever used HRT for 5 or fewer years or for more than 5 years were 1.07 (95% CI, 0.94-1.22) and 1.11 (95% CI, 0.92-1.35), respectively.
The FIGURE shows associations between duration of ever use of HRT for each tumor type. Similar to the ageadjusted associations, ever use of HRT appeared to be related only to an increased incidence of invasive carcinoma with a favorable histology. The RRs for this tumor type among women who reported ever using HRT for 5 or fewer years or for more than 5 years compared with never-users were 1.81 (95% CI, 1.07-3.07),and2.65(95%CI,1.34-5.23), respectively (P for trend = .005). For both short-term (Յ5 years) and long-term (Ͼ5 years) HRT users, the RRs of invasive carcinoma with a favorable histology were statistically significantly greater than the RRs for DCIS (P for difference = .03 and .02, respectively) and for invasive ductal/lobular carcinoma (P for difference = .05 and .01, respectively).
Among the 37 105 women at risk for breast cancer, data on mammography screening were self-reported by 31 809 women who responded to the second follow-up survey. Women who reported ever using HRT for 5 or fewer years and for more than 5 years were more likely to report that they had undergone mammography within 1 year before the survey (41% and 48%, respectively) than women who never used HRT (33%). Despite the apparent increased surveillance for women who reported ever HRT use, adjustment for mammography in the multivariate model had no marked effect on the associations of hormone use with any histological type of breast cancer. Among women who reported ever using HRT for 5 or fewer years, the RRs of DCIS, invasive carcinoma with a favorable histology, and invasive ductal or lobular carcinoma were 0.83 (95% CI, 0.46-1.48 who reported past HRT use for more than 5 years compared with neverusers, there was a 2.7-fold increased incidence of invasive carcinoma with a favorable histology. Among current hormone users, the RRs of invasive carcinoma with a favorable histology were 4.42 and 2.63 for 5 or fewer years and more than 5 years of use, respectively. The incidence of invasive ductal or lobular carcinoma was not associated with past HRT use, but there was a marginally statistically significantly increased risk associated with current use (RR, 1.38; 95% CI, 1.03-1.85).
COMMENT
A priori breast tumors were classified according to their histological and prognostic characteristics. 13 This classification allowed us to investigate differences in associations of breast cancer risk with HRT use across tumor types more fully than previous studies that compared in situ carcinomas with all invasive carcinomas combined. [8] [9] [10] In this study, we observed a positive, dose-response relationship between duration of postmenopausal hormone use and the incidence of breast cancer with a favorable prognosis; this relationship appeared to be stronger for current users compared with past users. Conversely, the incidence of DCIS and invasive ductal or lobular carcinoma were not related to ever use of hormones in this cohort. The data, however, are suggestive of a modest increased risk of invasive ductal or lobular carcinoma among women who, at baseline, reported current HRT use for 5 or fewer years.
Few studies have examined the effect of HRT use on risk of histologically defined breast cancer. [8] [9] [10] At least 2 studies reported a higher risk of in situ carcinoma compared with invasive carcinoma associated with postmenopausal hormone use. 8, 9 For example, in the Breast Cancer Detection and Demonstration Project, there was a 1.9-fold increased risk of in situ breast cancer among long-term hormone users (Ͼ10 years) compared with never-users, whereas duration of use was not associated with risk of invasive carcinoma. 8 Conversely, in a population-based casecontrol study of middle-aged women, Stanford et al 10 found no association with postmenopausal hormone use for in situ or invasive breast cancer. A significant increase in risk of invasive breast cancer with a favorable histology or with DCIS among HRT users provides a plausible explanation for the lower breast cancer mortality rates (or improved survival) among hormone users observed in some, [21] [22] [23] [24] but not all 25, 26 epidemiological studies. Unfortunately, we could not evaluate differences in breast cancer mortality between hormone users and nonusers for each tumor type because only 11 women with DCIS, 7 women with a favorable histological type of breast cancer, and 179 women with invasive ductal or lobular carcinoma died during follow-up. Further stratification of these deaths by HRT use would result in too few deaths in any strata, and comparisons of mortality rates by HRT use across tumor type would yield inconclusive estimates. There are several possible reasons for a specific risk association of HRT with breast cancer with a favorable histology. For example, an increased risk of in situ carcinoma and a reduced breast cancer mortality rate for women using postmenopausal hormones may be attributed to increased medical surveillance among hormone users compared with nonusers. The frequency of medical surveillance does not explain the increased incidence of tumors with a favorable histology, as observed in this study, since these tumors are not precursor lesions for the more common infiltrating ductal or lobular carcinomas. Adjustment for mammography use had no effect on the observed associations.
Shairer et al 8 proposed that the observed risk differences across tumor types could be due to a selective biological effect of hormone use on the growth of less aggressive breast tumors. In a recent study of 477 women with breast cancer, Holli et al 27 reported that breast tumors among HRT users were smaller, better differentiated, and had lower mean tumor proliferation rate as measured by the Sphase fraction. The results of that study are similar to other studies showing that breast tumors among estrogen users ap- Relative risks have been adjusted, using Cox proportional hazards regression, for age, body mass index, body mass index at age 18 years, waist-to-hip ratio, age at menarche, age at menopause, type of menopause, parity, age at first birth, family history of breast cancer in a first-degree relative, and alcohol intake. pear to be well-differentiated, 28 with fewer cells in mitosis. 29 Similarly, endometrial tumors that develop in estrogen users also appear to be more highly differentiated and rarely invade deeply in the myometrium. 30 It is important to recognize the potential limitations of this study. First, breast cancer histology was recorded by Surveillance, Epidemiology and End Results personnel from pathology reports, and was not determined by a single reference laboratory. Although the assessment of tumor histology may vary among pathologists, these variations would probably not result in spuriously elevated associations because HRT exposure was assessed prior to diagnosis. Second, it is unlikely that the pathologist would know exposure status. Third, it is improbable that women who developed invasive breast cancer with a favorable histology during follow-up were more likely to overestimate their hormone use at baseline than women who developed DCIS or invasive ductal or lobular carcinoma. In this study, we could not determine the effect of type of HRT because data regarding the type of postmenopausal hormones used (ie, combined estrogen-progesterone vs estrogen alone) were not available from the 1986 baseline questionnaire. Based on results of other studies, 31, 32 it is estimated that in this cohort approximately 20% of current hormone users and a smaller proportion of former users were prescribed combination HRT in 1986.
In conclusion, the results of this study provide important new data suggesting that postmenopausal hormone use is associated with an increased incidence of invasive breast cancer with a favorable histology, and there is little evidence of associations with DCIS or invasive ductal or lobular carcinoma. If confirmed by other studies, this information could have important public health implications given the widespread use of HRT among postmenopausal women in the United States. 33 Moreover, although breast cancer is the most commonly diagnosed cancer among women in the United States, 34 only a small proportion (Ͻ15%) of invasive cancer cases are of a favorable histological type. 13 If HRT use selectively increases the risk of the less commonly occurring tumors with a good prognosis, then the overall risks and benefits of hormone use in the population should be reexamined. Furthermore, this information would be particularly useful to clinicians assisting patients in making informed decisions regarding postmenopausal hormone use. Further research is needed to corroborate the results of this study and should include a large series of breast cancer cases with information available on type of HRT to explore differences in association between hormone use and invasive breast cancer risk across tumor types more fully.
